are biological preparations that stimulate or strengthen a person’s immune system against cancer. Cancer vaccines are usually administered intravenously. They can be used in both adults and children. The vaccines can be broadly classified into two: prophylactic and therapeutic vaccines. #Prophylacticvaccines
are used for the prevention of cancer, whereas #therapeuticvaccines
are used for treatment of cancer.
The analysts forecast the global cancer vaccines market to grow at a CAGR of 27.24% over the period 2014-2019.
This report covers the present scenario and the growth prospects of the global #cancer
vaccines market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various therapeutic and prophylactic cancer vaccines.
This report covers the present scenario and the growth prospects of the global cancer vaccines market for the period 2015-2019 in the following three regions:
Americas: The principal countries focused upon in this region are the US, Canada, Mexico, and Brazil
EMEA: The principal countries focused upon in this region are the UK; Germany; Italy; France; Spain and Middle Eastern and African countries such as Israel, South Africa, Egypt, Sudan, Kuwait, Saudi Arabia, Qatar, and UAE
APAC: The principal countries focused upon in this region are Japan, China, Australia, Singapore, South Korea, and India. APAC is one of the major markets that is untapped by the leading vendors.
The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the market. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.
The report, Global Cancer Vaccines Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, EMEA, and APAC; it also covers the global cancer vaccines market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Other Prominent Vendors
Increased Prevalence of Cancers
Cold Chain Management